HCV-Associated Lymphomas

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 4, 2003, Pages 406-423

  Fiorilli, Massimo ^a   Mecucci, Cristina ^b   Farci, Patrizia ^c   Casato, Milvia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS PROTEIN;

ANTIGEN RECOGNITION; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GRADING; CLONE; CROSS REACTION; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CHROMOSOME ABERRATIONS; CRYOGLOBULINEMIA; DISEASE PROGRESSION; FORECASTING; GENES, BCL-2; HEPACIVIRUS; HEPATITIS C; HUMANS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MODELS, BIOLOGICAL;

EID: 1342325549     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359-362, 1989.
2. Feinstone SM, Kapikian AZ, Purcell RH, et al. Transfusion-associated hepatitis not due to viral hepatitis type A or type B. N Engl J Med, 292: 767-770, 1975.
3. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 244: 362-364, 1989.
4. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med, 321: 1494-1500, 1989.
5. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med, 327: 1899-1905, 1992.
6. Houghton M. The hepatitis C viruses. Eds. Hagedorn C and Rice CM (eds). Springer, Berlin, pp 327-339, 2000.
7. Domingo E and Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol, 51: 151-178, 1997.
8. Farci P and Purcell RH. Clinical significance of hepatitis C virus genotypes and quasi-species. Semin Liver Dis, 20: 103-126, 2000.
9. World Health Organization: Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat, 6: 35-47, 1999.
10. Alter HJ and Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis, 20: 17-35, 2000.
11. Farci P, Alter HJ, Wong D, et al. A Long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med, 325: 98-104, 1991.
12. Fried MW, Schiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347: 975-982, 2002.
13. Mehta S, Levey JM, Bonkovsky HL. Extrahepatic manifestations of infection with hepatitis C virus. Clin Liver Dis, 5: 979-1008, 2001.
14. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol, 88: 392-394, 1994.
15. Mazzaro C, Zagonel V, Monfardini S, et al. Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol, 94: 544-550, 1996.
16. Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood, 10: 4296-4301, 1996.
17. Luppi M, Grazia Ferrari M, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia, 10: 351-355, 1996.
18. Luppi M, Longo G, Ferrari MG, et al. Clinicopathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol, 9: 495-498, 1998.
19. De Rosa G, Gobbo ML, De Renzo A, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol, 55: 77-82, 1997.
20. De Vita S, Zagonel V, Russo A, et al. Hepatitis C virus, non Hodgkin's lymphomas and hepatocellular carcinoma. Br J Cancer, 77: 2032-2035, 1998.
21. Vallisa D, Bertè R, Rocca A, et al. Association between hepatitis C virus and non-Hodgkin's lymphoma and effects of viral infection on histologic subtype and clinical course. Am J Med, 106: 556-560, 1999.
22. Montella M, Crispo A, Frigeri F, et al. HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity. Leuk Res, 25: 775-781, 2001.
23. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multi-center case-control study. Blood, 102: 996-999, 2003. [Epub 2003 Apr 24]
24. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-Cell Non-Hodgkin Lymphoma. Ann Intern Med, 127: 423-428, 1997.
25. Izumi T, Sasaki R, Tsunoda S, et al. B cell malignancy and hepatitis C virus infection. Leukemia, 11: 516-518, 1997.
26. Kumagawa M, Suzumiya J, Ohshima K, et al. Splenic lymphoproliferative disorders in human T lymphotropic virus type-I endemic area of Japan: clinicopathological, immunohistochemical and genetic analysis of 27 cases. Leuk Lymphoma, 41: 593-605, 2001.
27. McColl MD and Tait RC. Hepatitis C virus infection in patients with lymphoproliferative disorders. Br J Heamatol, 92: 771-772, 1996.
28. Hanley J, Jarvis L, Simmonds P, et al. HCV and non-Hodgkin lymphoma. Lancet, 347: 1339, 1996.
29. Germanidis G, Haloun C, Pourquier J, et al. Hepatitis C virus infection in patients with overt B cell non-Hodgkin's lymphoma in a French center. Blood, 93: 1778-1779, 1999.
30. Collier JD, Zanke B, Moore M, et al. No association between hepatitis C and B-cell lymphoma. Hepatology, 29: 1259-1261, 1999.
31. Thaien DJ, Raemaekers J, Galama J, et al. Absence of hepatitis C virus infection in non-Hodgkin's lymphoma. Br J Haematol, 96: 872-882, 1997.
32. Pioltelli P, Gargantini L, Cassi E, et al. Hepatitis C virus in Non-Hodgkin's Lymphoma. A reappraisal after a prospective case-control study of 300 patients. Am J Hematol, 64: 95-100, 2000.
33. Hausfater P, Cacoub P, Sterkers Y, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol, 67: 168-171, 2001.
34. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood, 91: 2433-2442, 1998.
35. De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood, 96: 3578-3584, 2000.
36. Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol, 15: 382-386, 1992.
37. Moldvay J, Deny P, Pol S, et al. Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. Blood, 83: 269-273, 1994.
38. Muratori L, Gibellini D, Lenzi M, et al. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood, 88: 2768-2774, 1996.
39. Boisvert J, He XS, Cheung R, et al. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis, 184: 8278-35, 2001.
40. Koike K, Tsutsumi T, Fujie H, et al. Molecular mechanism of viral hepatocarcinogenesis. Oncology, 62: 29-37, 2002.
41. De Vita S, De Re V, Sansonno D, et al. Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori, 88: 400-406, 2002.
42. Giannini C, Caini P, Giannelli F, et al. Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. J Gen Virol, 83: 1665-1671, 2002.
43. Fornasieri A, Bernasconi P, Ribero ML, et al. Hepatitis C virus (HCV) in lymphocyte subsets and in B lymphocytes expressing rheumatoid factor cross-reacting idiotype in type II mixed cryoglobulinaemia. Clin Exp Immunol, 122: 400-403, 2000.
44. Pileri P, Uematsu Y, Campagnoli et al. Binding of hepatitis C virus to CD81. Science, 282: 938-941, 1998.
45. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol, 16: 89-106, 1998.
46. Zuckerman E, Slobodin G, Kessel A, et al. Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection. Clin Exp Immunol, 128: 353-358, 2002.
47. Curry MP, Golden-Mason L, Doherty DG, et al. Expansion of innate CD5(pos) B cells expressing high levels of CD81 in hepatitis C virus infected liver. J Hepatol, 38: 642-650, 2003.
48. Wack A, Soldaini E, Tseng C, et al. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol, 31: 166-175, 2001.
49. Chan CH, Hadlock KG, Foung SK, et al. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood, 97: 1023-1026, 2001.
50. Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood, 98: 3745-3749, 2001.
51. Gorevic PD and Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol, 28: 79-94, 1991.
52. Agnello V, Zhang QX, Abel G, et al. The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia. Clin Exp Rheumatol, 13: S101-S104, 1995.
53. De Re V, De Vita S, Marzotto A, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer, 87: 211-216, 2000.
54. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum, 42: 2507-2516, 1999.
55. Pascual M, Perrin L, Giostra E, et al. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis, 162: 569-750, 1990.
56. Casato M, Taliani G, Pucillo LP, et al. Cryoglobulinaemia and hepatitis C virus. Lancet, 337: 1047-1048, 1991.
57. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinaemia. Clin Exp Rheumatol, 9: 621-624, 1991.
58. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med, 327: 1490-1495, 1992.
59. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology, 106: 1291-1300, 1994.
60. Knight G and Agnello V. WA monoclonal rheumatoid factors and non-Hodgkin lymphoma. Blood, 97: 3319-3321, 2001.
61. Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol, 159: 253-261, 2001.
62. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood, 95: 3878-3884, 2000.
63. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases. Medicine, 80: 1-8, 2001.
64. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol, 19: 111-129, 1997.
65. Monteverde A, Ballarè M, Bertoncelli MC, et al. Lymphoproliferation in type II mixed cryoglobulinemia. Clin Exp Rheumatol, 13: S141-S147, 1995.
66. La Civita L, Zignego AL, Monti M, et al. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum, 38: 1859-1560, 1995.
67. Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood, 84: 3047-3453, 1994.
68. Rasul I, Shepherd FA, Kamel-Reid S, et al. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology, 29: 543-547, 1999.
69. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer, 77: 2604-2613, 1996.
70. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum, 43: 94-102, 2000.
71. Sansonno D, De Vita S, Iacobelli AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol, 160: 3594-601, 1998.
72. Racanelli V, Sansonno D, Piccoli C, et al. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol, 167: 21-29, 2001.
73. Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med, 197: 939-945, 2003.
74. Knight GB, Agnello V, Bonagura V, et al. Human rheumatoid factor cross-idiotypes. IV. Studies on WA XId-positive IgM without rheumatoid factor activity provide evidence that the WA XId is not unique to rheumatoid factors and is distinct from the 17.109 and G6 XIds. J Exp Med, 178: 1903-1911, 1993.
75. Barbouche MR, Guilbert B, Makni S, et al. Common idiotypes expressed on human, monoclonal, abnormal immunoglobulins and cryoglobulins with polyreactive autoantibody activities. Clin Exp Immunol, 91: 196-201, 1993.
76. Ubara Y, Hara S, Katori H, et al. Splenectomy may improve the glomerulopathy of type II mixed cryoglobulinemia. Am J Kidney Dis, 35: 1186-1192, 2000.
77. Carbonari M, Tedesco T, Fiorilli M. Human peripheral B cells: A different cytometric point of view. Cytometry, 53: 97-102, 2003.
78. Zuckerman E, Zuckerman T, Sahar D, et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood, 97: 1555-1559, 2001.
79. Cottrez F, Auriault C, Capron A, et al. Analysis of the V beta specificity of super-antigen activation with a rapid and sensitive method using RT-PCR and an automatic DNA analyser. J Immunol Methods, 172: 85-94, 1994.
80. Giovannetti A, Mazzetta F, Caprini E, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood, 100: 4082-4089, 2002.
81. Casato M, Lilli D, Donato G, et al. Occult hepatitis C infection in type II mixed cryoglobulinemia. J Viral Hepat, in press.
82. Hayakawa K, Asano M, Shinton SA, et al. Positive selection of natural autoreactive B cells. Science, 285: 113-116, 1999.
83. Koenig-Marrony S, Soulas P, Julien S, et al. Natural autoreactive B cells in transgenic mice reproduce an apparent paradox to the clonal tolerance theory. J Immunol, 166: 1463-1470, 2001.
84. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol, 10: 637-645, 1999.
85. Zucca E, Bertoni F, Roggero E, et al. The gastric marginal zone B-cell lymphoma of MALT type. Blood, 96: 410-419, 2000.
86. Du M-Q and Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol, 3: 97-104, 2002.
87. Baliga BC and Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol, 20: 63-74, 2002.
88. Weiss LM and Warnke RA, Sklar J, et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med, 317: 1185-1189, 1987.
89. Jacobson JO, Wilkes BM, Kwaiatkowski DJ, et al. bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer, 72: 231-236, 1993.
90. Zignego AL, Giannelli F, Marrocchi ME, et al. Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and hepatitis C virus-positive liver diseases. Clin Exp Rheumatol, 15: 711-712, 1997.
91. Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology, 31: 474-479, 2000.
92. Kitay-Cohen Y, Amiel A, Hilzenrat N, et al. Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood, 96: 2910-2912, 2000.
93. Zuckerman E, Zuckerman T, Sahar D, et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol, 112: 364-369, 2001.
94. Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med, 137: 571-580, 2002.
95. Poetsch M, Weber-Matthiesen K, Plendl HJ, et al. Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation. J Clin Oncol, 14: 963-969, 1996.
96. Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood, 102: 1196-1201, 2003. [Epub 2003 Apr. 10].
97. Ascoli V, Lo Coco F, Artini M, et al. Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol, 109: 600-609, 199.
98. Casato M, Mecucci C, Agnello V, et al. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood, 99: 2259-2261, 2002.
99. Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood, 85: 2000-2004, 1995.
100. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood, 87: 299-307, 1996.
101. Brynes RK, Almaguer PD, Leathery KE, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol, 9: 995-1000, 1996.
102. Sole F, Woessner S, Florensa L, et al. Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma. Br J Haematol, 98: 446-449, 1997.
103. Hernandez JM, Garcia JL, Gutierrez NC, et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol, 158: 1843-1850, 2001.
104. Troussard X, Mauvieux L, Radford-Weiss I, et al. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Francais d'Hematologie Cellulaire (GFHC) study. Br J Haematol, 101: 712-721, 1998.
105. Gruszka-Westwood AM, Matutes E, Coignet LJ, et al. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol, 104: 600-604, 1999.
106. Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol, 161; 81-88, 2002.
107. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 99: 1299-1304, 2002.
108. Hermine O, Lefrere F, Bronowicki JP, et al. Patients with splenic lymphoma with villous lymphocytes associated with hepatitis C infection may enter in complete clinical response after reduction of viral load [abstract]. Blood, 94(suppl 1): 660a, 1999.
109. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med, 347: 89-94, 2002.
110. Emens LA and Sulkowski MS. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med, 347: 2168-2169, 2002.
111. Gruszka-Westwood AM, Hamoudi RA, Matutes E, et al. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood, 97: 3552-3558, 2001.
112. Mateo M. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol, 154: 1583-1589, 1999.
113. Lefrère F, Troussard X, Hermine O. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med, 347: 2169-2170, 2002.
114. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol, 17: 3835-3849, 1997.